IL1B and Parkinson disease: Concerning PD, MCC950 was found to inhibit the activation of the NLRP3 inflammasome in the SN and consequently inhibit IL-1β production, improving behavioral impairments, reducing nigrostriatal dopaminergic neuronal degeneration, and disrupting the accumulation of α-Syn inside and outside the nigrostriatal pathway [100,101].